Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602597 | 0.89 | ATM (0.56) | ATMELANECTSKCYP3A4TSHR | |
| SCHEMBL4676446 | 0.83 | CTSK (0.66) | CTSKCTSLCTSS | |
| SCHEMBL4674921 | 0.80 | CTSK (0.65) | CTSKCTSLCTSS | |
| SCHEMBL4674918 | 0.80 | CTSK (0.65) | CTSKCTSLCTSS | |
| SCHEMBL4675533 | 0.80 | KMT2A (0.46) | ATMITGB3ITGAVITGA2BCYP3A4 | |
| SCHEMBL4678519 | 0.75 | CTSK (0.53) | ATMCTSKCTSLCTSS | |
| SCHEMBL8530402 | 0.75 | ATM (0.68) | ATMELANECTSKCYP3A4TSHR | |
| SCHEMBL21469067 | 0.75 | ATM (0.68) | ATMELANECTSKCYP3A4TSHR | |
| SCHEMBL30460502 | 0.75 | ATM (0.68) | ATMELANECTSKCYP3A4TSHR | |
| SCHEMBL28546805 | 0.74 | CTSK (0.62) | ATMELANECTSKCTRB1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | CTSZ, CTSE, CTSS | ATM 3863/4885ELANE 206/4885ITGB3 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.